Journal profile
Cancer Translational Medicine
ISSN 2395-3012 · Wolters Kluwer Medknow Publications · India
Cancer Translational Medicine: fully open access; review about 9 weeks (community reports); 0 articles in 2025.
The latest issue on the journal's website is from December 2016 (Volume 2, Issue 6): the journal may have stopped publishing or moved platform in the last two years. Check its website before submitting.
Scope
Aims, scope and focus
Cancer Translational Medicine is published by Wolters Kluwer Medknow Publications. By OpenAlex counts of its recent articles, its largest topics are MicroRNA in disease regulation, Glioma Diagnosis and Treatment and Cancer-related molecular mechanisms research, together about 27.1% of its articles. Its main subfields are Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Translational Medicine is an open-access and peer-reviewed online journal with Bimonthly print on demand compilation of issues published.
From the journal's Aims & Scope
Main research topics OpenAlex counts of recent articles; shares are approximate
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology10.2%
- Glioma Diagnosis and TreatmentMedicine9%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology7.8%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology6%
- Cancer Cells and MetastasisMedicine5.4%
- Cancer Immunotherapy and BiomarkersMedicine4.2%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology4.2%
- Advanced Radiotherapy TechniquesPhysics and Astronomy4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
Indexed in: no record yet.
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
DOAJPublisher website
Other: Google Scholar, EBSCO, ProQuest, CNKI, Baidu
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- h-index
- 13OpenAlex ·
- i10-index
- 20OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 142 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 0 | 0 | 24 |
| 2025 | 0 | 0 | 69 |
| 2024 | 0 | 0 | 77 |
| 2023 | 0 | 0 | 108 |
| 2022 | 0 | 0 | 121 |
| 2021 | 0 | 0 | 152 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 9 weeksLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessLetPub
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- original articleCholine kinase inhibitors synergize with TRAIL in the treatment of colorectal tumors and overcomes TRAIL resistance Juan Carlos Lacal, Ladislav Andera Aim: The …Length not stated
- reviewMicroRNA regulating metabolic reprogramming in tumor cells: New tumor markers Daniel Otero-Albiol, Blanca Felipe-Abrio Metabolic reprogramming is a feature of c…Length not stated
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wolters Kluwer Medknow Publications
- Country or region
- India
- Language
- English
- ISSN
- 2395-3012
- Latest issue on the website
- Volume 2, Issue 6 (December 2016)
- Official links
- Journal homepage ↗LetPub
FAQ
Frequently asked questions about Cancer Translational Medicine
How long does peer review take at Cancer Translational Medicine?
Authors report an average review time of about 9 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cancer Translational Medicine?
The journal's website lists DOAJ; that list has not been checked against each database.
Is Cancer Translational Medicine open access, and what is the APC?
Cancer Translational Medicine is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .